Institute of Oncology Ljubljana, Department of Medical Oncology, Ljubljana, Slovenia.
Radiol Oncol. 2014 Nov 5;48(4):403-7. doi: 10.2478/raon-2013-0081. eCollection 2014 Dec.
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an entity with aggressive behaviour. One year of adjuvant trastuzumab significantly improves the disease free survival in the range of 40-50% and reduces the risk of dying from HER2 positive breast cancer by one third. Adjuvant treatment with trastuzumab became available in Slovenia in 2005 and the aim of this study is to explore, if the exceptional results reported in adjuvant clinical trials are achieved also in daily clinical practice.
An analysis of tumour and patient characteristics, type of treatment and outcome (relapse free and overall survival) of 313 patients (median age 52 years) treated at the Institute of Oncology Ljubljana in years 2005-2009 was performed.
Median follow-up was 4.4 years. Sixty-one patients relapsed and 24 died. Three and four years relapse free survival was 84.2% and 80.8% and the overall survival was 94.4% and 92.5%, respectively. Independent prognostic factors for relapse were tumour grade (HR 2.10; 95% CI 1.07-4.14; p = 0.031) and nodal stage (HR 1.35; 1.16-1.56; p < 0.0001) and for the overall survival nodal stage only (HR 1.36; 1.05-1.78; p = 0.021).
The outcome in patients with adjuvant trastuzumab in daily clinical practice, treated by medical oncologists, is comparable to results obtained in international adjuvant studies.
人表皮生长因子受体 2（HER2）阳性乳腺癌是一种侵袭性疾病。曲妥珠单抗辅助治疗 1 年可显著改善无病生存率（40-50%），并将死于 HER2 阳性乳腺癌的风险降低三分之一。曲妥珠单抗辅助治疗于 2005 年在斯洛文尼亚上市，本研究旨在探讨辅助临床试验中报告的优异结果是否也能在日常临床实践中实现。
对 2005-2009 年在卢布尔雅那肿瘤研究所接受治疗的 313 例（中位年龄 52 岁）患者的肿瘤和患者特征、治疗类型以及结局（无复发生存和总生存）进行分析。
中位随访时间为 4.4 年。61 例患者复发，24 例患者死亡。3 年和 4 年无复发生存率分别为 84.2%和 80.8%，总生存率分别为 94.4%和 92.5%。独立的预后因素包括肿瘤分级（HR 2.10；95%CI 1.07-4.14；p=0.031）和淋巴结分期（HR 1.35；1.16-1.56；p<0.0001）以及总生存的淋巴结分期（HR 1.36；1.05-1.78；p=0.021）。
接受医学肿瘤学家治疗的接受曲妥珠单抗辅助治疗的患者的结局与国际辅助研究中获得的结果相当。
